Article | January 17, 2020

6 Reasons Why Early Oncology Drug Trials Fail (And How To Avoid Them)

Customer Experience Initiatives Are Failing

Unfortunately, not all oncology trials succeed. In fact, the phase success and likelihood of approval (LOA) rates for oncology are the lowest across major therapeutic areas. Although there are many reasons for these relatively poor success rates, issues determining dose, schedule, and regimen in early phase trials are among the most prominent.

Why and Where Early Oncology Trials Fail

The main failure in oncology trials happens in Phase 2. According to research published by M. Hay et al. in 2014, oncology trials have phase success and LOA rates comparable to other therapeutic areas, such as infectious disease and endocrinology, between Phase I and II trials. It's between Phases 2 and 3 that success rates for oncology dip, a discrepancy that is then compounded in the following Phase 3 to regulatory approval transition.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: